shutterstock_1952148841_postmodern_studio
Postmodern Studio / Shutterstock.com
8 March 2022GenericsAlex Baldwin

Cipla files defensive patent suit over Ofev generic

Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev (Nintedanib) does not infringe two patents.

Cipla filed the complaint with the US District Court for the District of Delaware on Friday, requesting that the document be sealed.

In the accompanying motion to seal, Cipla explains that it has submitted an abbreviated new drug application (ANDA) to the Food and Drug Administration (FDA) seeking approval to manufacture and sell generic Nintedanib capsules.

As the complaint contains “sensitive, non-public information” related to its Anda, Cipla requested that portions of the document should be sealed.

The sensitive information includes information pertaining to “Cipla’s regulatory strategies, and confidential communications between Cipla and Boehringer”, the company claims.

The court granted the motion to seal on Monday, March 7, claiming that Cipla had “good cause” to seal. The court has now issued summons to Boehringer.

In a parallel filing, Cipla notified the  US Patent and Trademark Office that action had been filed in relation to two Boehringer patents, US patent 9,907,756 B2 and 10,105,323 B2.

Both patents are titled “Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative”.

Ofev is a blockbuster drug for Boehringer, netting €2 billion ($2.1 billion) in sales in 2020, making it the company’s second-biggest revenue-generating drug behind its type 2 diabetes treatment Jardiance (empaglflozin).

In 2020, the FDA approved Ofev for wider use to treat other lung diseases, as it was initially developed as a treatment for idiopathic pulmonary fibrosis.

Cipla has been approached for comment.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 August 2020   Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

More on this story

Americas
11 August 2020   Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

More on this story

Americas
11 August 2020   Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
Americas
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.
Big Pharma
25 April 2023   Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.